Recent, rapid advancements in the understanding of genetic causes of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) paved the way for development of gene-targeted genetic therapies tailored toward individual patients.1 Genetic testing to evaluate for the neurodegenerative conditions is an increasingly vital component in the diagnosis and management of individuals affected by ALS or FTD.
Frontotemporal dementia and ALS Test menu
Our FTD and ALS evaluations include both targeted panels and single gene evaluations to confirm and clarify diagnosis. Using next-generation sequencing, our assays provide improved coverage, offering increased sensitivity at above 99% for single nucleotide variants, above 94% for deletions/insertions less than 40 base pairs (bp), and above 95% for deletions up to 75 bp and insertions up to 47 bp.
Fill out the form below and one of our specialists will be in touch.